The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5)
Xiaoqing Ye1, Gang Chen2, Jia Jin1
1College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Abstract:
Mixed Lineage Leukemia 1 (MLL1), an important member of Histone Methyltransferases (HMT) family, is capable of catalyzing mono-, di-, and trimethylation of Histone 3 lysine 4 (H3K4). The optimal catalytic activity of MLL1 requires the formation of a core complex consisting of MLL1, WDR5, RbBP5, and ASH2L. The Protein-Protein Interaction (PPI) between WDR5 and MLL1 plays an important role in abnormal gene expression during tumorigenesis, and disturbing this interaction may have a potential for the treatment of leukemia harboring MLL1 fusion proteins. In this review, we will summarize recent progress in the development of inhibitors targeting MLL1- WDR5 interaction.
Insights
Targeting the Mixed Lineage Leukemia 1 (MLL1) and WDR5 protein interaction shows promise for treating MLL1-related leukemias. This review covers recent advancements in developing inhibitors for this crucial interaction.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Mixed Lineage Leukemia 1 (MLL1) is a key Histone Methyltransferase (HMT) catalyzing Histone 3 lysine 4 (H3K4) methylation.
- MLL1's catalytic activity depends on a core complex including MLL1, WDR5, RbBP5, and ASH2L.
- The MLL1-WDR5 Protein-Protein Interaction (PPI) is implicated in aberrant gene expression driving tumorigenesis.
Purpose of the Study:
- To review recent progress in developing inhibitors targeting the MLL1-WDR5 interaction.
- To explore the therapeutic potential of disrupting this PPI in leukemia treatment.
Main Methods:
- Literature review of recent studies on MLL1-WDR5 inhibitors.
- Analysis of the role of MLL1-WDR5 interaction in leukemia pathogenesis.
Main Results:
- Several inhibitors targeting the MLL1-WDR5 interaction have been developed.
- These inhibitors show potential for treating leukemias with MLL1 alterations.
Conclusions:
- Disrupting the MLL1-WDR5 interaction is a viable therapeutic strategy for MLL1-driven leukemias.
- Further research into MLL1-WDR5 inhibitors is warranted for leukemia treatment.
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Protein-protein Interfaces
Conservation of Protein Domains
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
What are Proteins?


